Maxing Shigan Decoction Mitigates Mycoplasma pneumonia-Induced Pyroptosis in A549 Cells via the NLRP3 Inflammasome
Authors Liu F, Liu TT, Sun M, Zhou JM, Xue F, Chen SH, Chen J, Zhang L
Received 20 November 2020
Accepted for publication 19 February 2021
Published 3 March 2021 Volume 2021:14 Pages 859—867
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Héctor M. Mora-Montes
Fang Liu,1,2,* TianTian Liu,2,* Min Sun,2 JingMin Zhou,2 Feng Xue,2 ShuangHui Chen,2 Jia Chen,3 Lei Zhang1
1Department of Pediatrics, Pudong New Area People’s Hospital, Shanghai, 201200, People’s Republic of China; 2Department of Pediatrics, East Hospital Affiliated to Tongji University, Shanghai, 200123, People’s Republic of China; 3Department of Traditional Chinese Medicine, Shanghai Children’s Medical Center, Shanghai, 200127, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Lei Zhang; Jia Chen Email [email protected]; [email protected]
Background: Mycoplasma pneumoniae is a predominant cause of community-acquired respiratory infections. We recently discovered the clinical efficacy of Maxing shigan decoction (MXSG) in M. pneumoniae infection and designed a study to explore the mechanism of action.
Methods: Serum IL-1β, IL-18, and TNF-α, and transcript expression of the NLR Family, Pyrin Domain Containing Protein 3 (NLRP3) were measured in the peripheral blood mononuclear cells (PBMCs) of 30 children with M. pneumoniae infection and 30 healthy donors. An in vitro model of M. pneumoniae infection in A549 cell culture was used to explore the curative effects and mechanisms of MXSG. Pyroptosis was measured by flow cytometry with activated caspase-1 and propidium iodide staining. IL-1β, IL-18, and TNF-α, and NLRP3 transcript expression were measured by qRT-PCR. Protein expression of NLRP3, Caspase-1, pro-caspase-1, IL-1β, pro-IL-1β, and GSDMD-N was determined by Western blotting. Experimental confirmation was performed in NLRP3-overexpressing A549 cells and in the presence of an NLRP3 inhibitor, INF39.
Results: M. pneumoniae infection-induced IL-1β, IL-18, TNF-α, and mRNA expression of NLRP3 in PBMCs and promoted pyroptosis in A549 cells. It also induced IL-1β, IL-18, TNF-α, and up-regulated NLRP3, ro-IL-1β, Caspase-1, Pro-Caspase-1, and GSDMD-N in culture. Similar to the NLRP3 inhibitor INF39, MXSG (0.1, 0.2, and 0.4 mg/mL) suppressed pyroptosis induced by M. pneumoniae infection and decreased IL-1β (P < 0.001), IL-18, TNF-α in culture. MXSG down-regulated NLRP3, pro-IL-1β, Caspase-1, pro-Caspase-1, and GSDMD-N in infected cultures and mitigated NLRP3 overexpression-induced pyroptosis.
Conclusion: MXSG mitigates M. pneumoniae-induced pyroptosis in A549 cells via the NLRP3 inflammasome.
Keywords: Mycoplasma pneumoniae, pyroptosis, Maxing shigan decoction, NLRP3 inflammasome
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]